United Therapeutics (UTHR) Total Non-Current Liabilities (2009 - 2026)

United Therapeutics has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $607.8 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 15.31% year-over-year to $607.8 million; the TTM figure through Jun 2026 stood at $607.8 million (up 15.31% YoY), while the FY2025 annual figure was $560.6 million, down 24.05% from the prior year.
• Total Non-Current Liabilities came in at $607.8 million for Q2 2026 at United Therapeutics, up from $599.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q3 2023 to a low of $527.1 million in Q2 2025.
• Average Total Non-Current Liabilities over 5 years is $905.2 million, with a median of $996.4 million recorded in 2024.
• Year-over-year, Total Non-Current Liabilities sank 43.46% in 2025 and gained 15.31% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $1.1 billion in 2022, then retreated by 3.39% to $1.1 billion in 2023, then plunged by 33.17% to $738.1 million in 2024, then slipped by 24.05% to $560.6 million in 2025, then climbed by 8.42% to $607.8 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $607.8 million in Q2 2026, $599.1 million in Q1 2026, and $560.6 million in Q4 2025.